Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.69 |
| ▸ | MAOA | P21397 | 2/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.69 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935244 | 1.00 | MAOB (0.69) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL994279 | 0.88 | MAOB (0.62) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL8935332 | 0.86 | GID4 (0.62) | MAOBMAOA | |
| Hydrochloric Acid SCHEMBL30001586 | 0.86 | MAOB (0.60) | MAOBMAOASCN9APARP10PPARA | |
| SCHEMBL994999 | 0.85 | MAOB (0.65) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL993071 | 0.85 | MAOB (0.65) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL993070 | 0.85 | MAOB (0.65) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL992772 | 0.84 | MAOB (0.60) | MAOBMAOASCN9AGRM5PPARA | |
| SCHEMBL8431815 | 0.82 | MAOB (0.67) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL1534881 | 0.82 | MAOB (0.63) | MAOBMAOASCN9APARP10PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694014-B2 | Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2017-07-04 | — | — | US | disclosed |
| US-20150290201-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | UNIV PADOVA (IT) | 2015-10-15 | — | — | US | disclosed |
| US-8487008-B2 | Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2013-07-16 | — | — | US | disclosed |
| US-20120329800-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | UNIVERSITA' DEGLI STUDI DI PADOVA, (UNIVERSITY OF PADUA) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290201-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | MAOA, MAOB, MUSK | MAOB 2/4885MAOA 1/4885SCN9A 2530/4885 |
| US-20120329800-A1 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS | MAOA, MAOB, MUSK | MAOB 2/4885MAOA 1/4885SCN9A 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.